Back to Search
Start Over
Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies
- Source :
- Blood; November 2018, Vol. 132 Issue: Supplement 1 p2294-2294, 1p
- Publication Year :
- 2018
-
Abstract
- Oliva: Sanofi: Consultancy, Speakers Bureau; La Jolla: Consultancy; Amgen: Consultancy, Speakers Bureau; Celgene: Consultancy, Other: Royalties, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau. Ionova:BMS: Research Funding; Takeda: Research Funding.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 132
- Issue :
- Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs53601022
- Full Text :
- https://doi.org/10.1182/blood-2018-99-117094